Polynovo (ASX:PNV) — Material Events
ASX:PNV · 6 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
PolyNovo grows revenue 16% as US burn approval enters final preparationMedium
PolyNovo posts 16.1% FY26 revenue growth and advances U.S. burn device approval strategy
15 Sept 2026
·Annual Report
·86
PolyNovo Accelerates Growth with 26% Sales Surge and New Manufacturing CapacityMedium
PolyNovo posts 26% sales growth in 1H FY26 with strong U.S. expansion and positive cash flow
19 Jan 2026
·Trading Update
·85
PolyNovo’s Revenue Surges 25% Amid R&D Setbacks and FDA PrepMedium
PolyNovo H1 FY26 revenue up 25%, profit near breakeven due to R&D fire and FDA prep
20 Feb 2026
·Half-Year Financial Report
·85
PolyNovo Reports 16% Revenue Growth and Strong Cash Flow in FY26Medium
PolyNovo FY26 trading update shows strong revenue growth and improved cash flow
23 July 2026
·Trading Update
·85
PolyNovo FY26 Revenue Climbs 16% While Net Profit Slips Amid Fire-Related Write-OffMedium
PolyNovo FY26 sales up 16.7%, EBITDA up 50%, NovoSorb MTX sales nearly double
26 Aug 2026
·Annual Financial Results
·85
No articles in this tier for the last 12 months.
Market Mentions
7
- appeared in market wrap coverage
These are market wrap articles where Polynovo (ASX:PNV) was mentioned. They reflect broader market coverage, not company-specific announcements.
Market Wrap - Week 38 (14 Sept -> 18 Sept) 2026
19 Sept 2026
Healthcare Wrap - Week 35 (24 Aug -> 28 Aug) 2026
29 Aug 2026
Healthcare Wrap - Week 30 (20 July -> 24 July) 2026
25 July 2026
Healthcare Wrap - Week 22 (25 May -> 29 May) 2026
30 May 2026
Market Wrap - Week 8 (16 Feb -> 20 Feb) 2026
21 Feb 2026